A detailed history of Pro Share Advisors LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 23,807 shares of COGT stock, worth $193,074. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,807
Previous 17,028 39.81%
Holding current value
$193,074
Previous $143,000 79.72%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.24 - $11.48 $55,858 - $77,822
6,779 Added 39.81%
23,807 $257,000
Q2 2024

Aug 13, 2024

SELL
$6.01 - $9.04 $31,119 - $46,809
-5,178 Reduced 23.32%
17,028 $143,000
Q1 2024

May 08, 2024

BUY
$4.38 - $9.02 $12,934 - $26,636
2,953 Added 15.34%
22,206 $149,000
Q4 2023

Feb 14, 2024

BUY
$4.06 - $10.08 $12,707 - $31,550
3,130 Added 19.41%
19,253 $113,000
Q3 2023

Nov 13, 2023

BUY
$9.69 - $13.34 $24,854 - $34,217
2,565 Added 18.92%
16,123 $157,000
Q2 2023

Aug 10, 2023

BUY
$9.85 - $13.24 $11,613 - $15,609
1,179 Added 9.52%
13,558 $160,000
Q1 2023

May 11, 2023

SELL
$10.04 - $15.5 $16,455 - $25,404
-1,639 Reduced 11.69%
12,379 $133,000
Q4 2022

Feb 02, 2023

BUY
$10.65 - $14.84 $15,229 - $21,221
1,430 Added 11.36%
14,018 $162,000
Q3 2022

Nov 04, 2022

BUY
$9.39 - $16.99 $118,201 - $213,870
12,588 New
12,588 $188,000
Q2 2022

Aug 01, 2022

SELL
$3.92 - $9.73 $43,515 - $108,012
-11,101 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$5.31 - $8.7 $13,981 - $22,907
-2,633 Reduced 19.17%
11,101 $83,000
Q4 2021

Feb 08, 2022

BUY
$7.51 - $10.81 $103,142 - $148,464
13,734 New
13,734 $118,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $533M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.